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Background  2 
Lack of achievement of secondary prevention objectives in patients with ischemic heart disease 3 






We aimed at evaluating the 6-month efficacy of an intensive lipid-lowering intervention, 6 
coordinated by nurses and implemented after hospital discharge, in patients hospitalized for an 7 
IHD event. 8 
Methods 9 
Pilot randomized controlled trial enrolling 78 patients (39 in each arm). A nurse-led intervention 10 
including follow-up, serial lipid level controls, and subsequent optimization of lipid-lowering 11 
therapy, was compared to standard of care in terms of serum lipid-level control at 6 months after 12 
discharge. 13 
Results 14 
The nurse-led intervention was associated with an improved management of LDL cholesterol 15 
levels compared to standard of care alone: LDL cholesterol levels ≤100 mg/dL were achieved in 16 
97% participants in the intervention arm as compared to 67% in the standard care arm (p value 17 
<0.001), the LDL cholesterol ≤70 mg/dL target recommended by the 2016 European Society of 18 
Cardiology guidelines was achieved in 62% vs 37% participants (p value 0.047), and the LDL 19 
cholesterol reduction ≥50% recommended by the American College of Cardiology/American 20 
Heart Association in 2013 was achieved in 25.6% participants in the intervention arm as 21 
compared to 2.6% in the standard care arm (p value 0.007). The intervention was also associated 22 
with improved blood pressure control among individuals with hypertension. 23 
5 
 
Conclusions  1 
Our findings highlight the opportunity that nurse-led, intensive, post-discharge follow-up plans 2 
may represent for achieving LDL cholesterol guideline-recommended objectives in patients with 3 
IHD. These findings should be replicated in larger cohorts.  4 
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ABBREVIATIONS AND ACRONYMS 1 
CRP  cardiac rehabilitation program 2 
ESC  European Society of Cardiology 3 
EUTERPE Estudio de UTilización del chronic care model en pacientes isquémicos de 4 
Elevado Riesgo mediante un Proceso basado en Enfermería (Spanish acronym) 5 
IHD  ischemic heart disease 6 
LDL   low density lipoprotein 7 
NSTEMI non-ST elevation myocardial infarction 8 






 Despite landmark primordial and primary preventive efforts,
1,2
 as well as dramatic 4 
improvements in the acute-phase care of ischemic heart disease (IHD) patients attained in the last 5 
three decades,
3–5
 IHD remains one of the leading causes of death worldwide.
5,6
   6 
Among the prevailing unmet needs in the care of these patients, lack of achievement of 7 
secondary prevention targets after an acute IHD event is currently considered a key issue.
7,8
 8 
Specifically, although the guidelines of the European Society of Cardiology (ESC) recommend 9 
that patients with overt IHD should be treated aggressively to achieve low density lipoprotein 10 
(LDL) cholesterol levels ≤70 mg/dL,
7,9
 this treatment goal is often not achieved.
8
 Poor adherence 11 
to lifestyle recommendations and pharmacological therapies by patients
10
, as well as time 12 




Studies suggest that specialized post-discharge follow-up by trained nurses represents an 15 
opportunity to improve the care and outcomes of patients with cardiovascular diseases.
14–16
 16 
Nurses may have more availability than physicians to conduct close follow-up, and may 17 
communicate with patients more effectively, particularly in terms of health education. 18 
Specifically, follow-up by specialized nurses has become a key component of chronic disease 19 
management programs for patients with chronic diseases, such as heart failure.
14
 However, 20 
whether this approach may also be beneficial for patients with IHD is less understood.  21 
 Our aim was thus to evaluate the 6-month efficacy of an intensive lipid-lowering 22 
intervention, coordinated by a nurse and implemented after hospital discharge, in patients 23 
hospitalized for an IHD event. For this purpose, we conducted a randomized, controlled trial in 24 
8 
 
which this intervention was compared to the standard of care, in terms of use of lipid-lowering 1 
therapies and lipid-level control at 6 months after discharge. 2 
 3 
Materials and Methods 4 
Study context 5 
 Since 2007, a multi-disciplinary cardiac rehabilitation program (CRP) is in place in our 6 
center. The CRP is coordinated by nurses and includes interventions performed by cardiologists, 7 
nurses, rehabilitation physicians, physiotherapists, and mental health professionals. All patients 8 
discharged from our center after a hospitalization for an acute IHD event and with no severe 9 
cognitive impairment are invited to the CRP; of them, those willing to participate enter the 10 
program. As part of the program activities, nurses educate patients in healthy habits during the 11 
in-hospital stage as well as in follow-up visits at 3 and 12 months after discharge; monitor 12 
quality of life, anxiety and depression symptoms using validated tests; and coordinate the follow-13 
up plan. Rehabilitation physicians and physiotherapists assess the functional status of the patient 14 
and recommend and supervise physical activity during follow-up. All professionals involved in 15 
the CRP participate in monthly group sessions aimed at reinforcing the health education of the 16 
patients, with a special focus on increasing the patients’ understanding of the pathophysiology of 17 
IHD and on the importance of optimal risk factor management, particularly through physical 18 
activity and adherence to pharmacotherapies. Because of its characteristics, the CRP provides an 19 
excellent platform to implement additional secondary prevention interventions.  20 
Trial design and study participants 21 
 The Estudio de UTilización del chronic care model en pacientes isquémicos de Elevado 22 
Riesgo mediante un Proceso basado en Enfermería (EUTERPE, Spanish acronym)
 
study was a 23 
9 
 
single-center, unblinded, randomized controlled pilot trial assessing the efficacy and safety of a 1 
specialized, nurse-guided, lipid-lowering intervention aimed at improving the management of 2 
LDL cholesterol levels and other cardiovascular risk factors in patients hospitalized for IHD. 3 
Between April 1
st
, 2012 and February 28
th
, 2013, all patients hospitalized for IHD in our 4 
center meeting inclusion criteria in the local CRP and willing to participate in the program, were 5 
screened for inclusion in this study. This included patients hospitalized for ST-segment elevation 6 
and non ST-segment elevation myocardial infarction (STEMI and NSTEMI, respectively), 7 
unstable angina, and stable angina. Of them, all patients providing written informed consent were 8 
included in the EUTERPE. The study was approved by the Ethics Committee of the Hospital del 9 
Mar and was conducted in accordance with the Declaration of Helsinki. 10 
Interventions 11 
 Participants were randomized in a 1:1 ratio to two management arms (Figure 1). The 12 
“standard care arm” involved usual post-discharge follow-up, which in our healthcare area 13 
typically involves follow-up by the patient’s primary care general physician, plus follow-up by a 14 
primary care cardiologist for a limited period of time; and inclusion in the standard CRP (see 15 
Study Context for more details). 16 
On the other hand, the “intervention arm” involved usual post-discharge follow-up, 17 
inclusion in the standard CRP, plus the following additional interventions: 1) follow-up by a 18 
CRP nurse, who coordinated all “intervention arm” actions; 2) conduct of serum lipid level 19 
controls at months 3 and 6 after discharge; 3) evaluation of laboratory test results using a pre-20 
specified algorithm based on clinical practice guidelines and developed ad-hoc for this study 21 
(Supplementary Figure S1); 4) prescription and dispensing of any additional / alternative lipid 22 
lowering treatment, if indicated according to the algorithm, by a cardiologist involved in the 23 
10 
 
CRP; and 5) communication at three and six months with the patient and with the patient’s 1 
primary care physician (phone, e-mail) regarding any laboratory test results and therapeutic 2 
changes during the intervention. 3 
Randomization to the two study arms was performed using a computer-generated 4 
randomization scheme. Study participants and personnel were aware of, i.e. not blinded to, the 5 
study intervention.  6 
Study endpoints 7 
The primary study endpoint was the proportion of patients with serum LDL cholesterol 8 
levels ≤70 mg/dL at 6 months of follow-up in each study arm, which is the treatment goal 9 
supported by current ESC guidelines.
7,9
 Other variables related to lipid management assessed at 6 10 
months included lipid-lowering medication use at 6 months, changes in lipid-lowering 11 
medication, changes in lipid levels as compared to hospital discharge, and proportion of 12 
individuals with a reduction in LDL cholesterol ≥50%, among others. In 2012, atorvastatin was 13 
the mostly used high intensity statin in our center. For patients treated with other statins, the 14 
atorvastatin equivalent daily dose was calculated using an equivalence chart generated by clinical 15 
pharmacy specialists. 16 
As other secondary study endpoints, we also assessed the impact of the intervention in 17 
terms of control of other cardiovascular risk factors: proportion of patients with systolic blood 18 
pressure <140 mmHg and diastolic blood pressure <90mmHg at 6 months; proportion of patients 19 
in which blood-pressure medication had changed at 6 months compared to discharge; levels of 20 
glycosilated haemoglobin (HbA1c); and proportion of active smokers (all after 6 months of 21 
follow-up). Although these are not directly related to the study intervention, which was focused 22 
on lowering LDL cholesterol, we hypothesized that a greater number of contacts with specialized 23 
11 
 
nurses would lead to an improved management also of other risk factors. As tertiary study 1 
endpoints, we also assessed the frequency of urgent hospitalization and of all-cause death after 6 2 
months of follow-up. 3 
 Because the safety of achieving LDL cholesterol levels <70mg/dL and of aggressive LDL 4 
cholesterol management has been largely described in the literature,
2,17,18
 no safety endpoints 5 
were evaluated in this pilot analysis.  6 
Sample size 7 
 Although initially, based on local event rates as well as on the RCT-based effect of statins 8 
in LDL cholesterol levels we estimated a sample size of 118 participants (59 per study arm using 9 
a 1:1 randomization) for the present study to have sufficient statistical power, in an interim 10 
analysis (conducted when 96 patients had already been screened for inclusion, 78 of them 11 
accepting inclusion in the study [39 patients per arm]), we already observed statistically 12 
significant differences between the two study groups in terms of the primary endpoint. Based on 13 
this, and in a context of funding limitations for the study, we decided to finalize the study 14 
recruitment. 15 
Statistical analyses 16 
Baseline characteristics of the study participants were described using number and 17 
proportion for categorical variables, and median (interquartile range) for continuous variables. 18 
Differences between the two study arms were compared using chi-square statistics or Fisher’s 19 
exact test for categorical variables, as needed, and non-parametric tests for continuous variables 20 
in order to account for the small sample size. The same tests were used to compare the two study 21 
arms after 6 months of follow-up. There were no losses to follow-up during the study period, and 22 
no cross-overs between study arms happened either.  23 
12 
 
The absolute atorvastatin dose change at 6 months and the absolute change in LDL 1 
cholesterol levels at 6 months were described graphically, for both study arms. 2 
 All statistical analyses were performed using Stata Version 15.0.
19
 A p value of <0.05 3 
was used to define statistical significance. 4 
 5 
Results 6 
Study participants 7 
 Between April 1
st
, 2012 and February 28
th
, 2013, 96 IHD patients discharged after an 8 
IHD-related hospitalization met the inclusion criteria of the CRP, and were therefore screened 9 
for inclusion in the study. Of them, 78 provided written informed consent, while 18 refused 10 
participating in the study. The 78 patients included in the study were randomized in a 1:1 ratio to 11 
either the standard care arm or to the study intervention arm (N = 39 each).  Figure 1 displays 12 
the flow of the patients included in the study.  13 
Baseline characteristics 14 
 The baseline characteristics of the study participants (i.e., at hospital discharge) are 15 
summarized in Table 1. Overall, the median age of the study population was 61 years, and 83% 16 
were male. There were no statistically significant differences between the 2 study groups in 17 
terms of baseline sociodemographic characteristics and other cardiovascular risk factors, in the 18 
reason for hospitalization, or in laboratory test results at admission. This included identical 19 
median baseline LDL cholesterol levels (103 mg/dL in both arms). There was a trend towards a 20 
higher median HbA1c in the intervention arm (6.1% as compared to 5.7% in the standard care 21 
arm) although this was not statistically significant. 22 
13 
 
At hospital discharge, 100% of patients in the intervention arm and 97.4% patients in the 1 
standard care arm received statins, with atorvastatin being the most frequently used option. The 2 
median equivalent daily dose of atorvastatin was identical in the two groups (40mg per day). 3 
Lipid-lowering management and lipid level endpoints at 6 months of follow-up 4 
 Table 2 summarizes the study results in terms of lipid management at 6 months after 5 
discharge. Briefly, although statin use remained very high in both study arms, the equivalent 6 
daily dose of atorvastatin was higher in the intervention group (Figure 2A), and use of ezetimibe 7 
was more frequent among the patients in the intervention arm. Median total and LDL cholesterol 8 
levels were lower in the intervention arm, and the relative change in LDL cholesterol levels at 6 9 
months was larger in the intervention arm than in the standard care arm (-36% reduction vs -26% 10 
reduction) (p 0.025). The distribution of absolute changes in LDL levels by study arm is 11 
presented in Figure 2B. 12 
 In this context, the primary study endpoint (proportion of patients with LDL ≤70mg/dL at 13 
6 months of follow-up) was achieved more frequently in the intervention arm (62%) than in the 14 
standard care arm (37%) (p 0.047). The less strict target of LDL cholesterol <100 mg/dL was 15 
achieved by 97.3% and 66.7% of participants, respectively (p<0.001). Also, a LDL-cholesterol 16 
reduction ≥50% was more frequently attained in the intervention arm compared to the standard 17 
care arm (26% vs 3%) (p value 0.007). 18 
Management of other cardiovascular risk factors 19 
 Table 3 summarizes the management of other relevant cardiovascular risk factors at 6 20 
months of follow-up. Compared to the standard care arm, there was a trend towards a better 21 
management of blood pressure levels (systolic and diastolic blood pressure simultaneously 22 
meeting pre-specified targets) in the intervention arm compared to the standard care arm, 23 
14 
 
diastolic blood pressure levels being significantly lower in the intervention arm. When only 1 
individuals with a prior diagnosis of hypertension were compared, the frequency of patients 2 
simultaneously meeting systolic and diastolic blood pressure targets was also significantly higher 3 
in the intervention arm. On the other hand, no differences were observed between study arms 4 
with regards to tobacco use at 6 months or HbA1c levels. 5 
Clinical events 6 
 Table 3 also presents the results regarding urgent hospitalizations and all-cause death at 6 7 
months of follow-up. During the study period, the number of hospitalizations was very few, and 8 
there were no deaths in any of the study arms. In this context, no statistically significant 9 
differences between the two study arms were identified.  10 
 11 
Discussion 12 
 In this pilot, randomized, controlled trial conducted in a single center in which a 13 
comprehensive CRP was in place, a nurse-led intervention including follow-up, serial lipid level 14 
controls, and subsequent optimization of lipid-lowering therapy if appropriate was associated 15 
with an improved management of LDL cholesterol levels compared to standard of care alone. 16 
Also, the intervention was associated with improved blood pressure control among individuals 17 
with a diagnosis of hypertension. If replicated in larger studies, the present findings may have 18 
important implications for the chronic management of patients with IHD, in many of whom the 19 
treatment goals recommended by clinical practice guidelines are currently not achieved. 20 
 In our study, despite being included in a comprehensive, multidisciplinary CRP, only 21 
37% of the individuals in the standard care arm achieved the LDL target of ≤70mg/dL 6 months 22 





 highlights the need for additional efforts aimed at improving adherence to and 1 
treatment titration of lipid-lowering medications in patients with IHD. Of note, despite the 2 
additional interventions included in the intervention arm, 38% of participants in this group still 3 
did not achieve the LDL ≤70mg/dL target, which stresses the complexity of the issue and the 4 
difficulty to achieve a full success in this patient population. 5 
Our results are consistent with those from prior studies assessing the efficacy of nurse-led 6 
cardiovascular risk reduction programs in patients with IHD. In the Randomised Evaluation of 7 
Secondary Prevention by Outpatient Nurse SpEcialists (RESPONSE) trial,
20,21
 which included 8 
754 patients from The Netherlands admitted for an acute coronary syndrome and exposed to a 9 
nurse-coordinated secondary prevention intervention (comprising 4 outpatient clinic visits to a 10 
cardiovascular nurse focused on healthy lifestyle recommendations, improvement of biometric 11 
risk factors and of medication adherence, and in which medication adjustment was conducted 12 
when necessary), there was a significant improvement in overall cardiovascular risk factor 13 
control, in 10-year estimated CVD death risk after 12 months, and in re-hospitalizations among 14 
individuals exposed to the intervention as compared to those in the standard care arm. 15 
Specifically regarding LDL cholesterol, although study nurses had been trained and were highly 16 
confident about their ability to achieve drug-related treatment targets,
22
 differences between the 2 17 
study arms were smaller than in our study, with a target of LDL cholesterol <2.5mmol/L 18 
(≈100mg/dL) being achieved in 80% of patients in the intervention arm compared to 69% in the 19 
standard care arm (as compared to 97% and 67%, respectively, in our study). Our results are also 20 
consistent with those from observational studies evaluating similar nurse-led programs,
23,24 
as 21 
well as with experimental evaluations conducted in other groups of cardiovascular patients.
16 
In 22 
this context, to our knowledge our analysis is the first to assess the efficacy of a nurse-based 23 
16 
 
intervention in terms of achieving the LDL target recommended in the 2016 ESC guidelines,
7
 as 1 
well as in terms of achieving the LDL reduction recommended in the 2013 American College of 2 
Cardiology / American Heart Association (ACC/AHA) cholesterol treatment guidelines.
25 
3 
Our findings have important clinical implications. The intervention, which could be 4 
easily incorporated to a standard CRP, resulted not only in clear benefits in terms of lipid level 5 
management, but also in improved management of blood pressure levels among individuals with 6 
hypertension. Because the intervention did not include any actions aimed at modifying the 7 
patient’s blood pressure lowering pharmacologic treatment, the latter was likely the consequence 8 
of the increased contact between the healthcare personnel and patients leading to greater 9 
adherence to healthy lifestyle recommendations. Our study identifies thus an invaluable 10 
opportunity to improve the secondary prevention management of patients with IHD.  11 
Study limitations 12 
 Some study limitations must be acknowledged. First, patients were recruited from a 13 
single medical center, therefore, generalizability of our findings to other patient populations and 14 
healthcare environments may be limited. Nevertheless, the benefits of closer follow-up observed 15 
in our study are likely to apply to other environments. Second, the small sample size may have 16 
impacted statistical power and our ability to identify statistically significant differences between 17 
the groups. This, however, did not prevent us from observing significant differences between the 18 
study arms in several endpoints, including the pre-specified primary study endpoint, which 19 
supports the efficacy of the intervention. On the other hand, our analysis was clearly 20 
underpowered to identify differences in clinical events, or in other study endpoints such as 21 
differences in tobacco use during follow-up. 22 
17 
 
Third, the small sample size also prevented conducting detailed evaluations of different 1 
lipid-lowering pharmacologic management strategies. For the same reason, subgroup analyses in 2 
clinically relevant subgroups of patients were not feasible either. Finally, because the study was 3 
conducted before 2015, this prevented gaining insights on the effectiveness specifically of 4 
PCSK9 inhibitors
26
 in patients with IHD. These limitations stress the pilot nature of the present 5 
analysis, and the need to replicate our findings in larger, multi-center, contemporary cohorts.  6 
  7 
Conclusions 8 
 In this small experimental study, a nurse-led intervention added to a standard CRP 9 
including follow-up, serial lipid level checks, and subsequent optimization of lipid-lowering 10 
therapy, was associated with a markedly improved management of LDL cholesterol levels 11 
compared to a standard CRP program alone. Our findings highlight the opportunity that nurse-12 
led post-discharge follow-up aggressive lipid-lowering interventions represent for the 13 
optimization of risk factor control, specifically of LDL cholesterol in patients with IHD.  14 
 15 
Implications for practice 16 
1. Strategies are needed to optimize secondary prevention in post-MI patients 17 
2. A nurse-led intervention improved LDL cholesterol control at 6 months 18 
3. Other risk factor-control benefits were also observed at 6 months 19 
4. Easily incorporable to a standard rehabilitation program 20 
 21 
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FIGURE LEGENDS 1 
Figure 1. Flow of the study participants. 2 
This flowchart displays the flow of the participants included in the study. There were no losses to 3 
follow-up or study arm crossovers during the 6-month study follow-up. 4 
Abbreviations: N = number 5 
 6 
Figure 2A. Absolute atorvastatin dose change at 6 months in milligrams per day, by study arm.   7 
Y axis: number of patients. 8 
 9 
Figure 2B. Absolute LDL cholesterol change at 6 months in, mg/dL, by study arm.   10 




Table 1. Baseline characteristics of the study participants. 2 
 Overall 
(N = 78) 
Standard Care 
(N = 39) 
Intervention 
(N = 39) 
P Value 
Sociodemographic characteristics and 
cardiovascular risk factors 
    
   Age, years 61 (54, 7) 60 (53, 7) 62 (55, 7) 0.382 
   Male sex 65 (83.3) 33 (84.6) 32 (82.1) 0.761 
   Active smoker 18 (23.1) 8 (20.5) 10 (25.6) 0.591 
   Diabetes mellitus 24 (30.8) 9 (23.1) 15 (38.5) 0.141 
   Hypertension 59 (75.6) 27 (69.2) 32 (82.1) 0.187 
   Dyslipidemia 51 (65.4) 25 (64.1) 26 (66.7) 0.812 
Clinical variables at discharge     
   Systolic blood pressure, mmHg 116 (108, 129) 115 (107, 128) 118 (109, 137) 0.385 
   Diastolic blood pressure, mmHg 71 (64, 7) 71 (64, 8) 70 (62, 7) 0.418 
   LVEF, % 60 (55, 6) 60 (49, 6) 60 (53, 6) 0.572 
Reason for hospitalisation                            
   STEMI 35 (44.9) 19 (48.7) 16 (41) 0.679* 
   NSTEMI 30 (38.5) 13 (33.3) 17 (43.6)  
   Unstable angina 12 (15.4) 6 (15.4) 6 (15.4)  
   Stable angina 1 (1.3) 1 (2.6) 0 (0)  
Laboratory test results at admission     
   Glucose, mg/dL 109 (98, 127) 109 (98, 136) 108 (98, 123) 0.642 
   Creatinine, mg/dL 0.80 (0.70, 1.00) 0.80 (0.70, 1.00) 0.90 (0.80, 1.00) 0.223 
   Urea, mg/dL 38 (28, 47) 34 (26, 45) 41 (30, 49) 0.053 
   Haemoglobin, g/dL 14.1 (13.2, 15.1) 14.2 (13.3, 15.1) 14.0 (12.8, 15.1) 0.549 
   HbA1c, % 5.8 (5.5, 6.6) 5.7 (5.4, 6.3) 6.1 (5.5, 7.0) 0.084 
   Total cholesterol, mg/dL 176 (150, 215) 178 (162, 216) 166 (136, 214) 0.393 
   LDL cholesterol, mg/dL 103 (84, 142) 103 (93, 140) 103 (79, 142) 0.566 
   HDL cholesterol, mg/dL 41 (32, 49) 44 (33, 55) 40 (28, 48) 0.193 
   Triglycerides, mg/dL 124 (99, 179) 119 (98, 179) 130 (104, 174) 0.693 




   Statin use at discharge 77 (98.7) 38 (97.4) 39 (100) 1.000* 
   Atorvastatin 65 (83.3) 31 (81.6) 34 (87.2) 0.755* 
   Simvastatin 2 (2.6) 1 (2.6) 1 (2.6)  
   Rosuvastatin 10 (12.8) 6 (15.8) 4 (10.3)  
   Equivalent daily dose of atorvastatin  40 (40, 40) 40 (40, 40) 40 (40, 40) 0.877 
 1 
Data presented as median (interquartile range) or n (%). Percentages may not sum 100% due to rounding 2 
*P value calculated using Fisher’s exact test 3 
Abbreviations: HbA1c = glycosilated haemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; 4 
LVEF = left ventricle ejection fraction; NSTEMI = non-ST elevation myocardial infarction; STEMI = ST elevation 5 
myocardial infarction  6 
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Table 2. Lipid-lowering medication use and serum lipid levels at 6 months of follow-up. 1 
 Standard Care 
(N = 39) 
Intervention 
 (N = 39) 
P Value 
Lipid-lowering medication use    
   Any statin, % 37 (94.9) 39 (100.0) 0.494* 
   Ezetimibe, % 1 (2.6) 11 (28.2) 0.003* 
   Lipid-lowering medication changed, % 8 (20.5) 19 (48.7) 0.009 
   Equivalent daily dose of atorvastatin, mg 40 (40, 40) 40 (40, 80) 0.045 
      Absolute change in daily dose of atorvastatin, mg 0 (0, 0) 0 (0, +40) 0.036 
      Relative change in daily dose of atorvastatin, % 0 (0, 0) 0 (0, +100) 0.036 
Laboratory test results    
   Total cholesterol, mg/dL 151 (129, 176) 130 (115, 147) <0.001 
      Absolute change in total cholesterol, mg/dL -45 (-63, -3) -43 (-70, -14) 0.635 
      Relative change in total cholesterol, % -24 (-33, -1) -25 (-37, -9) 0.389 
   LDL cholesterol, mg/dL 82 (63, 108) 67 (60, 78) 0.006 
      Absolute change in LDL cholesterol, mg/dL -35 (-42, +4) -34 (-69, -16) 0.062 
      Relative change in LDL cholesterol, % -26 (-38, +5) -36 (-54, -19) 0.025 
   HDL cholesterol, mg/dL 48 (41, 55) 43 (37, 50) 0.051 
      Absolute change in HDL cholesterol, mg/dL +6 (-6, +11) +5 (-4, +9) 0.581 
      Relative change in HDL cholesterol, % +13 (-11, +30) +11 (-8, +33) 0.964 
   Triglycerides, mg/dL 99 (77, 132) 95 (69, 114) 0.246 
      Absolute change in triglycerides, mg/dL -41 (-60, +13) -30 (-88, -6) 0.995 
      Relative change in triglycerides, mg/dL -28 (-43, +18) -27 (-51, -5) 0.686 
LDL cholesterol clinical management endpoints     
   LDL cholesterol ≤100 mg/dL 18 (66.7) 36 (97.3) 0.001* 
   LDL cholesterol ≤70 mg/dL 10 (37.0) 23 (62.2) 0.047 
   LDL reduction at 6months ≥50% 1 (2.6) 10 (25.6) 0.007* 
 2 
Data presented as median (interquartile range) or n (%). Percentages may not sum 100% due to rounding 3 
*P value calculated using Fisher’s exact test 4 
Abbreviations: HDL = high density lipoprotein; LDL = low density lipoprotein  5 
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Table 3. Management of other cardiovascular risk factors, and clinical events at 6 months of 1 
follow-up. 2 
 Standard Care 
(N = 39) 
Intervention 
 (N = 39) 
P Value 
Management of other cardiovascular risk factors at 
6 months 
   
   Systolic blood pressure, mmHg 130 (120, 140) 126 (119, 134) 0.270 
   Diastolic blood pressure, mmHg 76 (66, 82) 72 (62, 79) 0.038 
   SBP <140 and DBP <90 mmHg 26 (66.7) 33 (84.6) 0.065 
   Change in blood pressure-lowering medication 0 (0) 5 (12.8) 0.055* 
   HbA1c, %  5.8 (5.5, 6.3) 6.1 (5.9, 6.4) 0.123 
   Active smoker 4 (10.3) 3 (7.7) 1.000* 
Management of blood pressure in individuals with 
hypertension (n=59) 
   
   Systolic blood pressure, mmHg 132 (123, 144) 127 (120, 135) 0.114 
   Diastolic blood pressure, mmHg 76 (66, 85) 72 (64, 76) 0.044 
   SBP <140 and DBP <90 mmHg 17 (63.0) 28 (87.5) 0.035* 
   Change in blood pressure-lowering medication 0 (0.0) 4 (12.5) 0.118* 
Management of HbA1c in individuals with diabetes 
(n=24) 
   
   HbA1c, % 6.2 (5.8, 7.3) 6.4 (6.0, 7.2) 0.380 
   HbA1c <7.0% 5 (71.4) 7 (70.0) 1.000* 
Clinical events during follow-up    
   Urgent hospitalization 4 (10.3) 0 (0.0) 0.115* 
   All-cause death 0 (0.0) 0 (0.0) - 
 3 
Data presented as median (interquartile range) or n (%) 4 
*P value calculated using Fisher’s exact test 5 
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Figure 2A. Absolute atorvastatin dose change at 6 months in milligrams per day, by study arm.   1 
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Figure 2B. Absolute LDL cholesterol change at 6 months in, mg/dL, by study arm.  1 
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SUPPLEMENTARY FIGURES  1 
Figure S1. Lipid-lowering pharmacological algorithm in the intervention arm.  2 
 3 
Abbreviations: IHD = ischaemic heart disease; LDL = low density lipoprotein 4 
